Canaccord raised the firm’s price target on CervoMed (CRVO) to $27 from $21 and keeps a Buy rating on the shares. The firm raised its target following the release of impressive 32-week Phase 2b datafor neflamapimod in dementia with Lewy bodies (DLB). When viewed in the light of the unmet need in DLB, which remains very high, they believe regulatory alignment on a pivotal program design could drive upside from current levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- CervoMed’s Promising Clinical Trial Data and Strategic Focus Boost Buy Rating and Price Target
- CervoMed Announces Positive Phase 2b Trial Results
- CervoMed announces 32-week data from Extension phase of Phase 2b RewinD-LB
- CervoMed Stockholders Approve Key Proposals at Annual Meeting
- CervoMed appoints Marco Verwijs as EVP, technical operations